Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA before special items falls 1.3 percent to € 4.41 billion
Lupin updates on shipment of Mirabegron ER Tablets
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Sales reflect continued strong growth in oncology and vaccines
Submission based on results from pivotal phase III trial showing all primary endpoints met
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Subscribe To Our Newsletter & Stay Updated
